Table of Contents
Jefferies Global Healthcare Conference in London
Date: November 17-20, 2025
To view the webcast, please click here.
Jefferies Global Healthcare Conference in London
Related
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
Affinia Therapeutics announced Health Canada’s approval of its clinical trial application for AFTX-201, a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated dilated cardiomyopathy (DCM).
Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
Aspect Biosystems announced receiving a $79 million investment from the Government of Canada, supporting a $280 million, multi-year project to accelerate its pipeline of bioengineered cellular medicines for serious metabolic and endocrine diseases.
Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
BELMONT, Mass. – March 23, 2026 – Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced new clinical and neuroimaging data from an ongoing Phase 1b/2a study evaluating its autologous dopaminergic neuron replacement therapy for
Oryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders
BELMONT, Mass. – March 23, 2026 – Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, today announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing
Comments